Abstract: A 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention promotes the expression of the myogenic factors MyoG and MyHC while inhibiting the expression of the muscle atrophy factor atrogin-1, promotes the formation of myotubes, and inhibits myocyte apoptosis, and thus can promote myogenesis and inhibit muscle atrophy.

Abstract: The invention described here provides ready-to-use (RTU) pharmaceutical compositions in single unit dose packaging, such compositions including ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The compositions provided by the invention are stable when stored at 20° C. to 25° C.±2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use. In certain aspects, the invention comprises methods of using such compositions in the treatment of diseases, conditions, or symptoms related to vitamin C deficiency, such as, in specific embodiments, scurvy.

Abstract: The invention described here provides ready-to-use (RTU) pharmaceutical compositions in single unit dose packaging, such compositions including ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The compositions provided by the invention are stable when stored at 20° C. to 25° C.±2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use. In certain aspects, the invention comprises methods of using such compositions in the treatment of diseases, conditions, or symptoms related to vitamin C deficiency, such as, in specific embodiments, scurvy.

Abstract: The present invention describes slow-release compositions for the effective delivery of active ingredients such as putrescine and Vitamin C into the skin. These compositions may be used in a variety of cosmetic and therapeutic applications including for promoting wound healing, for reducing or preventing the formation of hypertrophic scar tissue, for reducing or preventing skin irritation and inflammation and/or for reducing or preventing skin's signs of aging.

Abstract: Disclosed are compounds which inhibit Pin1 activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysregulated Pin1 activity.

Abstract: The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

Abstract: The present disclosure relates to a formulation comprising voruciclib malonate. The present disclosure further provides a method of treating a blood cancer using the formulation and an optional BCL-2 inhibitor, administered on various dosage regimens.

Abstract: Provided herein are compositions relating to psychedelics and serotonin receptor modulators. Further provided herein are methods of treating a disease or disorder (e.g., depression or diseases or disorders related to depression) comprising administering psychedelics and serotonin receptor modulators.

Abstract: A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurological disease with molecules which binds multiple adjacent sites of the protein assemblies and allowing the molecules to bind multiple cites of the protein assemblies; and thereby impeding propagation of the disease-associated conformation of the protein in the environment. Drug/prion complexes are formed and uses of the drugs in detection and treatment of neurodegenerative diseases are disclosed.

Abstract: The present disclosure discloses use of ergothioneine (EGT) for the prevention or treatment of sepsis. The present disclosure studies the anti-inflammatory mechanism of ergothioneine in sepsis, aiming to provide a therapeutically effective dose and reveal the signaling pathway ergothioneine probably acts on in the treatment of sepsis, and provide experimental data support for the understanding of the mechanism behind the systemic inflammatory reactions of sepsis and for the use of ergothioneine as a new drug for treatment. The present disclosure also provides ergothioneine (EGT) loaded on a nanocarrier, and use thereof in the prevention or treatment of sepsis.

Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

Abstract: There is provided pharmaceutical compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

Abstract: Invention relates to use of antitumoral effective benzimidazole metal complex containing zinc having antitumoral effect, in treatment of cancer.

Abstract: A method of neuroinflammation and conditions associated therewith including chronic and acute conditions as well as specific and non-specific conditions. Oral dosage forms containing 640 mg micronized and non-micronized particulate metaxalone and excipients including alginic acid and propylene glycol alginate. The method includes inhibiting the monoamine oxidase A (MAO-A) enzyme as well as restoring/upregulating/increasing IL-13 and PGC-1?. The treated conditions, among others, include diabetic neuropathy, fibromyalgia, back pain, chronic pain induced depression, restless leg syndrome, anxiety, mood disorder, peripheral neuropathy, and herpetic neuralgia. The method further includes inducing or restoring homeostasis, restoring oxidative homeostasis, restoring basal phenotype from a neuroinflammatory state and improving neuroplasticity.

Abstract: The present invention addresses the problem of providing a pharmaceutical composition/drug combination which makes it possible to prevent and/or treat dyslipidemia such as hypercholesterolemia and hypertriglyceridemia, or cardiovascular diseases such as arteriosclerosis and cardiovascular events. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) ? agonist and an ATP citrate lyase (ACL) inhibitor for preventing and/or treating dyslipidemia such as hypercholesterolemia and hypertriglyceridemia, or cardiovascular diseases such as arteriosclerosis and cardiovascular events.

Abstract: Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders.

Abstract: An analgesic and antipruritic pharmaceutical composition, including PF-05089771 shown as and PF-04885614 shown as An application of the analgesic and antipruritic pharmaceutical composition in the treatment of a disease in which both a voltage-gated sodium channel 1.7 (Nav1.7) and a voltage-gated sodium channel 1.8 (Nav1.8) are involved.

Abstract: The subject invention pertains to tacrolimus compositions and a method for the treatment of symptoms of allergic conjunctivitis or keratoconjunctivitis, including, for example, ocular redness and ocular itchiness. The composition is preservative free and can be dispensed in a multidose container.

Abstract: Herein are provided a combination of everolimus and of amcenestrant or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a combination, and the therapeutic uses thereof, in particular for the treatment of cancer, including breast cancer.

Abstract: The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for binding or modulating a DDB1- and CUL4-associated factor 1 (DCAF1) protein. Further provided herein are ligand-DCAF1 complexes or in vivo modified DCAF1 proteins.

Abstract: The present disclosure relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one in treating kidney disease. According to the present disclosure, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one of the present disclosure palliates clinical symptoms and alleviates renal failure and renal injury through reduction of blood glucose levels and insulin resistance in diabetic nephrosis animal models. Thus, the compound may be advantageously applied to a use for preventing or treating kidney diseases, especially diabetic renal diseases.

Abstract: Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.

Abstract: Disclosed herein are methods of treatment or prevention of acute anxiety in an individual in need thereof. Such methods include administering to the individual an alpha 7 nicotinic acetylcholine receptor (?7 nAChR) modulator at a therapeutic dose to treat or prevent manifestations of the acute anxiety and symptoms thereof.

Abstract: Compound with formula (1) suitable for use in a method for treating a disease or disorder capable of being treated by an agonist of AdipoR. e.g. diabetic neuropathy. Also disclosed are related pharmaceutical compositions and medicaments, as well as a method for treatment of disorders including administering such compound, pharmaceutical composition, or medicament.

Abstract: The present disclosure provides methods and compositions for treating or limiting development of a lysosomal storage disorder, by administering to a subject that has or is at risk of a lysosomal storage disorder thereof an amount effective of a sortilin (SORT1) inhibitor to treat or limit development of the lysosomal storage disorder.

Abstract: The invention provides a method for applying diarylhydantoin compounds, including flutamide, bicalutamide, enzalutamide, apalutamide, and proxalutamide, to treat sepsis and conditions that mimic sepsis.

Abstract: Ion-pairs known as GUMBOS (group of uniform materials based on organic salts) from antiseptics (chlorhexidine and octenidine) and the beta-lactam antibiotic, ceftriaxone. The antimicrobial efficacy of these GUMBOS and unreacted stoichiometric equivalent mixtures were compared to ceftriaxone and azithromycin alone. On a molar basis, GUMBOS were equivalent to ceftriaxone and 10× more effective in killing N. gonorrhoeae than azithromycin. They were more than 100× more effective than either antibiotic in killing CRE. A strategy involving the electrostatic interaction between a common antiseptic and a discontinued antibiotic (octenidine and carbenicillin) was also evaluated as a treatment for gonorrhoea. Octenidine/carbenicillin is a novel group of uniform materials based on organic salts (GUMBOS) with inherent in vitro antibacterial activity that comes from its parent antiseptic and antibacterial ions, octenidine and carbenicillin, respectively.

Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: News methods, compositions and kits that comprise perampanel are provided for treating a subject having a SYNGAP1 neurodevelopmental disorder, including to treat conditions of sleep disorder, behavior problems and/or myoclonic or reflex seizures.

Abstract: The present invention relates to stable pharmaceutical compositions comprising apixaban or its pharmaceutically acceptable salts thereof. The present invention further relates to a capsule composition comprising a therapeutically effective amount of apixaban solubilized or dispersed in a pharmaceutically acceptable carrier, wherein the therapeutically effective amount of apixaban ranges from about 0.5 mg/unit dosage form to about 50 mg/unit dosage form. The present invention also provides manufacturing processes thereof and use of the said compositions for prevention, treatment or prophylaxis of disorders in human patients in need thereof.

Abstract: Provided are methods of improving the pharmacokinetics of migalastat by limiting caffeine intake during migalastat therapy.

Abstract: The invention relates to pharmaceutical compositions comprising (S)-1-(2-(trifluoromethyl)phenyl)sulfonyl)piperidine-3-carboxylic acid and their medical use, for example for use in the treatment of ?1-antitrypsin deficiency (AATD).

Abstract: Disclosed herein are methods treating prodromal HD in a subject, wherein the subject has at least 36 CAG repeats in the huntingtin (Htt) gene, wherein the method comprises administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.

Abstract: Methods are provided for treating cancer, particularly non-small cell lung cancers and pancreatic ductal adenocarcinomas, by administering both a sublethal dose of NAD(P)H:quinone oxidoreductase 1 (NQO1) bioactivatable drug and a sublethal dose of mesenchymal-epithelial transition factor (cMET) inhibitor to the cancer patient. Treatment of other cancers which overexpress cMET and NQO1 are also provided.

Abstract: Provided are compositions comprising nicorandil compound(s) in a controlled release formulation that releases at least about 30% of the nicorandil compound(s) into the intestine of human subjects. Such compositions can include a gastric acid dissolution susceptible component (GADSC) and a gastric acid dissolution resistant component (GADRC), wherein upon maintaining the composition in contact with a pH 1.2 dissolution media for a period of about 2 hours (1) the GADRC releases a statistically significantly smaller proportion of the one or more nicorandil compounds in the GADRC than the proportion of one or more nicorandil compounds release from the GADSC and (2) the composition releases no more than 50% of the one or more nicorandil compounds contained in the composition. The invention further provides methods of product such compositions and therapeutic uses of compositions, e.g., comprising once-daily administration of the composition to treat one or more diseases or conditions, including angina.

Abstract: Provided herein are methods of treating a cancer comprising administering an EGFR degrader to a patient suffering therefrom and subjecting the patient to radiation. The cancer can express mutant, overexpressed or overly activated EGFR, mutant KRAS, or mutant BRAF.

Abstract: Disclosed are methods of treating immunodeficiency virus infection that include methods of treating latent immunodeficiency virus infection in immune cells using a TGF-? inhibitor with antiretroviral therapy.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an inflammatory bowel disease with a lymphocyte function-associated antigen-1 antagonist.

Abstract: Provided is a method of treating a neurological or psychiatric disease or disorder in a patient in need thereof, comprising: administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to the patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.

Abstract: The present invention provides a pharmaceutical combination comprising a WRN inhibitor in combination with at least one additional therapeutically active agent. It also provides a method of treating cancer, involving administering to a subject in need thereof the WRN inhibitor in combination with the at least one additional therapeutically active agent. For example, the WRN inhibitor compound, or a pharmaceutically acceptable salt thereof, is of formula (I): wherein R1, R2, R3, R4, R5, R28, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein.

Abstract: Applicant discloses methods, uses, and compositions of heteroaryl ketone fused azadecalin compounds for treating patients suffering from Cushing's syndrome or Cushing's Disease (collectively “CS”) without causing significant QT interval prolongation (e.g., the QT interval following administration differs by no more than about 10 milliseconds from the baseline QT interval). Therapeutic amounts of the heteroaryl ketone fused azadecalin compounds may be between about 50 milligrams per day (mg/day) and up to about 500 mg/day, and in embodiments may be up to about 800 mg/day. The methods, uses, and compositions may reduce QT interval, and may be useful for treating QT prolongation in patients, including CS patients. The treatments may be oral treatments administered to a fasted patient, or to a fed patient. The heteroaryl ketone fused azadecalin compounds may be administered with a meal.

Abstract: A sustained-release injectable composition containing naltrexone, and a method for producing the same are described. The composition may prevent the initial burst release of naltrexone by controlling the release rate of naltrexone at a target site, and maintain a plasma naltrexone concentration sufficient to exhibit the effect of naltrexone by releasing naltrexone continuously for one month. In addition, the production method is capable of producing microparticles that are homogeneous and of good quality while having high encapsulation efficiency for naltrexone, a poorly soluble drug.

Abstract: There is a problem of providing a therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance.

Abstract: Formulations and methods for the preventative treatment of incidental opioid overdose comprising the intranasal (IN) administration of a pharmaceutical formulation containing the opioid antagonist nalmefene as a prophylactic measure.

Abstract: This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: The present invention relates to an anticancer composition containing as an active ingredient a compound inducing cell senescence and apoptosis. The compound of the present invention can discriminate cancer cells and normal cells and induce both cell senescence and apoptosis in a cancer cell-specific manner. Thus, the compound does not need the attachment of any cancer cell-specific targeting substance thereto, can minimize the frequent adverse effects caused by the attack of anticancer agents on normal cells, and exhibits a potent anticancer effect on the basis of the aforementioned dual action.

Abstract: Disclosed herein are methods of treating, preventing or ameliorating a disease or condition associated with cancer or a tumor. In some embodiments, the method includes administering a compound of Formula (I) to a subject in need thereof wherein the cancer or the tumor is or becomes resistant to one or more immune checkpoint inhibitors.